Back to Newsroom
Back to Newsroom

Small Cap Stocks To Watch - AMKR, AVNR, LOGM

Friday, 26 April 2013 09:02 AM

Topic:

Amkor Technology (Nasdaq: AMKR) $386. Announced Thursday after market close financial results for the first quarter ended March 31, 2013, with net sales of $688 million, net income of $13 million, and earnings per diluted share of $0.07.

"Driven by our strong performance in mobile communications, first quarter sales and earnings came in at the high end of our expectations," said Ken Joyce, Amkor's president and chief executive officer. "Our investments in the advanced technologies and production capacity in support of the fast-growing market for smartphones and tablets are paying off with notable improvement over the first quarter 2012."

Based upon currently available information, we have the following expectations for the second quarter 2013: Net sales of $730 million to $780 million, up 6% to 13% from the prior quarter. Gross margin of 17% to 20%. Net income of $18 million to $41 million, or $0.09 to $0.19 per diluted share. Capital additions of around $170 million.

What They Do: Amkor is a leading provider of semiconductor packaging and test services to semiconductor companies and electronics OEMs.

Avanir Pharmaceuticals (Nasdaq: AVNR) $3.20. Today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect (PBA), irrespective of neurologic cause. In addition, the CHMP also recommended approval of two dose strengths of NUEDEXTA; 20/10 mg and 30/10 mg capsules.

"The positive opinion from CHMP and recommendation for a broad PBA label for NUEDEXTA is a key step in the regulatory process toward having the first and only evidence-based treatment for PBA approved in the European Union," said Dr. Joao Siffert, chief scientific officer of Avanir. "We will continue to work with the European Medicines Agency and the European Commission toward the marketing authorization so that patients suffering from PBA have ready access to NUEDEXTA in Europe."

What They Do: Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need.

LogMeIn (Nasdaq: LOGM) $17.86. Announced Thursday after market close its results for the quarter ended March 31, 2013. For the first quarter of 2013, total revenue increased 15 percent to $37.4 million from $32.7 million reported in the first quarter of 2012.

Non-GAAP net income for the first quarter of 2013 was $3.1 million, or $0.12 per diluted share. Non-GAAP net income excludes $5.2 million in stock compensation expense, $6.1 million in patent litigation related expense and $1.1 million in acquisition related costs and amortization. This compares to Non-GAAP net income of $3.5 million, or $0.14 per diluted share, reported in the first quarter of 2012.

What They Do: LogMeIn provides the essential cloud-based collaboration, IT management, and customer service offerings required to empower, manage, secure and support the new mobile workplace.


About SmallCapReview

Copyright SmallCapReview. SmallCapReview.com has been a leading site for information on Small Cap Stocks, Penny Stocks and Microcaps since 1999. Visit http://SmallCapReview.com to sign up for our FREE newsletter.

Topic:
Back to newsroom
Back to Newsroom
Share by: